Ping Liu from 501 7Th St NE, Kasson, MN 55944, age 50, Phone: 9175172550

Us Patents

Radiolabeled Cannabinoid-1 Receptor Modulators
view source
US Patent:

7754188, Jul 13, 2010
Filed:

Jun 25, 2004
Appl. No.:

10/559228
Inventors:

H. Donald Burns - Harleysville PA, US
Alex M. Chen - Cranford NJ, US
Raymond E. Gibson - Holland PA, US
Mark T. Goulet - Westfield NJ, US
William K. Hagmann - Westfield PA, US
Terence G. Hamill - Lansdale PA, US
James P. Jewell - Jersey City NJ, US
Linus S. Lin - Westfield NJ, US
Ping Liu - Westfield NJ, US
Andrey V. Peresypkin - Cranford NJ, US
Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:

A61K 51/00
A61M 36/14
US Classification:

424 165, 424 189
Abstract:

The present invention relates to particular radiolabeled Cannabinoid-1 (CB1) receptor modulators, and methods of using these modulators for labeling and diagnostic imaging of Cannabinoid-1 receptors in mammals, particularly humans. In addition, intermediates useful for the synthesis of the radiolabeled Cannabinoid-1 receptor modulators are also disclosed, as well as the processes for synthesizing the radiolabeled Cannabinoid-1 receptor modulators. Still further, formulations of the radiolabeled Cannabinoid-1 receptor compounds are described.

Removal Of Carbon Dioxide From Air
view source
US Patent:

20100095842, Apr 22, 2010
Filed:

Nov 15, 2007
Appl. No.:

12/515259
Inventors:

Klaus S. Lackner - Dobbs Ferry NY, US
Ping Liu - Tucson AZ, US
International Classification:

B01D 53/62
B01J 20/34
US Classification:

95107, 502 22, 502 56
Abstract:

A process for removing COfrom the air, comprising the steps of (a) passing the air in contact with a first ion exchange resin to absorb COfrom the air; (b) passing a COsorbent in contact with the first ion exchange resin to transport COto the sorbent; passing the sorbent from step (b) in contact with a weak base anion exchange resin to absorb COfrom the sorbent; separating the COfrom the ion exchange resin by heating the ion exchange resin from step (c) whereby to drive off the COfrom the resin. Alternatively, the ion exchange resin may be washed with water prior to heating.

Oxazole Derivatives Useful As Inhibitors Of Faah
view source
US Patent:

20110021531, Jan 27, 2011
Filed:

Jul 27, 2009
Appl. No.:

12/509542
Inventors:

Harry CHOBANIAN - Aberdeen NJ, US
Linus S. Lin - Westfield NJ, US
Ping Liu - Westfield NJ, US
Marc D. Chioda - Metuchen NJ, US
Robert J. DeVita - Westfield NJ, US
Ravi P. Nargund - East Brunswick NJ, US
Yan Guo - Westfield NJ, US
International Classification:

A61K 31/497
C07D 413/14
A61K 31/444
A61K 31/501
A61P 25/00
A61P 19/00
US Classification:

51425203, 544405, 546256, 544238, 51425505, 514333
Abstract:

The present invention is directed to certain oxazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer Disease, and Parkinson's Disease.

Oxazole Derivatives Useful As Inhibitors Of Faah
view source
US Patent:

20110144119, Jun 16, 2011
Filed:

Jul 30, 2009
Appl. No.:

13/057415
Inventors:

Harry Chobanian - Aberdeen NJ, US
Linus S. Lin - Westfield NJ, US
Ping Liu - Westfield NJ, US
Marc D. Chioda - Metuchen NJ, US
Robert J. DeVita - Westfield NJ, US
Ravi P. Nargund - East Brunswick NJ, US
Yan Guo - Westfield NJ, US
International Classification:

A61K 31/501
C07D 413/14
A61K 31/497
C07D 413/04
A61K 31/444
A61K 31/4439
A61K 31/506
C07D 263/46
A61K 31/421
C07D 413/10
A61K 31/4245
C07D 413/12
A61K 31/4545
C07D 417/14
A61K 31/4725
A61K 31/4709
A61P 19/02
A61P 29/00
A61P 25/00
A61P 25/04
A61P 25/06
A61P 25/20
A61P 25/28
A61P 25/16
US Classification:

51425203, 544405, 51425505, 546256, 514333, 5462714, 514340, 544316, 514274, 548228, 514376, 548131, 514364, 544333, 514256, 544296, 546194, 514318, 544238, 5462697, 514342, 514341, 546141, 514309, 546167, 514314
Abstract:

The present invention is directed to certain oxazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.

Pharmaceutical Compositions For The Treatment Of Pain And Other Indications
view source
US Patent:

20130030000, Jan 31, 2013
Filed:

Jan 25, 2011
Appl. No.:

13/574303
Inventors:

Harry R. Chobanian - Aberdeen NJ, US
Linus S. Lin - Westfield NJ, US
Ping Liu - Westfield NJ, US
Marc D. Chioda - New Brunswick NJ, US
Robert J. DeVita - Westfield NJ, US
Ravi P. Nargund - East Brunswick NJ, US
Yan Guo - Westfield NJ, US
Terence G. Hamill - Lansdale PA, US
Wenping Li - Lansdale PA, US
Darrell Arthur Henze - Collegeville PA, US
International Classification:

A61K 31/497
A61K 31/506
A61K 31/513
A61K 31/4439
A61K 31/421
A61K 31/4245
A61K 31/4545
A61K 31/501
A61K 31/4725
A61K 31/4709
A61P 29/00
A61P 25/22
A61P 3/04
A61P 27/02
A61P 11/06
A61P 27/06
A61P 9/00
A61P 25/24
A61P 43/00
A61P 19/02
A61P 25/28
A61P 25/18
A61P 25/30
A61P 25/16
A61P 25/08
A61P 11/00
A61P 35/00
A61P 1/00
A61P 1/04
A61P 1/12
A61P 17/04
A61P 1/16
A61P 25/06
A61P 25/02
A61K 31/444
US Classification:

51425203, 51425505, 514333, 514274, 514340, 514376, 514364, 514318, 514342, 514309, 514314, 514341, 514334
Abstract:

The present invention is directed to a composition useful for the treatment of a FAAH mediated disease, disorder or conditions comprising a FAAH inhibitor and a second activation, comprising a selected imidazole or oxazole FAAH inhibitor and a second active agent. The compositions will be useful in the treatment of a wide range of disease, disorder, or conditions including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer disease, and Parkinson's disease. In another aspect the invention discloses herein is directed to compositions useful in the treatment of neuropathic and nociceptive pain, said compositions comprising etoricoxib.

Inhibitors Of Hif Prolyl Hydroxylase
view source
US Patent:

20170233412, Aug 17, 2017
Filed:

Sep 23, 2015
Appl. No.:

15/514536
Inventors:

- RAHWAY NJ, US
- SHANGHAI, CN
XIAOXING DU - SHANGHAI, CN
BYRON GABRIEL DUBOIS - NEW YORK NY, US
DEODIALSINGH GUIADEEN - CHESTERFIELD NJ, US
SHANKARAN KOTHANDARAMAN - PLAIN CITY OH, US
PING LIU - WESTFIELD NJ, US
RONGQIANG LIU - SHANGHAI, CN
WEIGUO QUAN - SHANGHAI, CN
CHRISTOPHER SINZ - MIDDLETOWN NJ, US
LIPING WANG - CRANBURY NJ, US
Assignee:

MERCK SHARP & DOHME CORP. - RAHWAY NJ
MSD R&D (CHINA) CO., LTD. - SHANGHAI
International Classification:

C07D 513/06
C07D 471/06
C07D 498/16
C07D 498/06
Abstract:

The present invention concerns compounds of formula I or pharmaceutically acceptable salts thereof, which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.

Trka Kinase Inhibitors, Compositions And Methods Thereof
view source
US Patent:

20170158698, Jun 8, 2017
Filed:

Mar 23, 2015
Appl. No.:

15/128782
Inventors:

Helen MITCHELL - West Point PA, US
Mark E. FRALEY - West Point PA, US
Andrew J. COOKE - West Point PA, US
Craig A. STUMP - West Point PA, US
Casey C. MCCOMAS - West Point PA, US
Kathy SCHIRRIPA - West Point PA, US
Melody MCWHERTER - West Point PA, US
Ping LIU - Rahway NJ, US
Dann PARKER - Kenilworth NJ, US
Chun Sing LI - Shanghai, CN
Qinghua MAO - Shanghai, CN
- Rahway NJ, US
Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:

C07D 487/04
C07D 231/40
C07D 417/12
C07D 401/04
C07D 417/14
C07D 471/04
C07D 401/14
C07D 403/04
C07D 403/12
C07D 413/12
C07D 413/14
C07D 277/46
C07D 403/14
Abstract:

The present invention is directed to substituted five membered heteroaryl benzamide compounds of formula (I) (Formula (I)) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

Trka Kinase Inhibitors, Compositions And Methods Thereof
view source
US Patent:

20170114056, Apr 27, 2017
Filed:

Mar 23, 2015
Appl. No.:

15/129206
Inventors:

Helen MITCHELL - West Point PA, US
Mark E. FRALEY - West Point PA, US
Andrew J. COOKE - West Point PA, US
Craig A. STUMP - West Point PA, US
Yi Heng CHEN - Rahway NJ, US
Douglas C. BESHORE - West Point PA, US
Casey C. MCCOMAS - Phoenixville PA, US
Kathy SCHIRRIPA - West Point PA, US
Melody MCWHERTER - Boyertown NJ, US
Swati P. MERCER - West Point PA, US
Keith P. MOORE - West Point PA, US
Ping LIU - Rahway NJ, US
Harold B. WOOD - Rahway NJ, US
Chun Sing LI - Shanghai, CN
Qinghua MAO - Shanghai, CN
- Rahway NJ, US
Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:

C07D 471/04
C07D 513/04
Abstract:

The present invention is directed to a bicyclic heteroaryl benzamide compounds of formula (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

Name / Title

Company / Classification

Phones & Addresses

Ping Liu
PRESIDENT

ASIAN RESTAURANT INC

83 Broad St, Middletown, CT 06457
7 Division St 2Fl, New York, NY 10002

Ping Liu
Manager

Cuspress, LLC

Ping Liu
Owner

China House
Ret Misc Homefurnishings

1944 S 60 St, Philadelphia, PA 19142
2157273345

Medicine Doctors

Dr. Ping Liu, Trenton NJ - MD (Doctor of Medicine)

view source

Specialties:

Internal Medicine

Address:

750 Brunswick Ave, Trenton, NJ 08638
6098157887 (Phone), 6093946776 (Fax)

16 James Trl, Long Valley, NJ 07853

175 High St, Newton, NJ 07860
9735798321 (Phone), 9735798807 (Fax)

CHILTON HOSPITAL
97 W Parkway, Pompton Plains, NJ 07444
9738315446 (Phone), 9738315443 (Fax)

Languages:

English

Ping Liu

view source

Specialties:

Internal Medicine

Work:

Newton Memorial Medical Center Hospitalist
175 High St FL 3, Newton, NJ 07860
9733832121 (phone), 9735798807 (fax)

Education:

Medical School
Tongji Med Univ, Wuhan City, Hubei, China
Graduated: 1992

Conditions:

Acute Pancreatitis
Bacterial Pneumonia
Cardiac Arrhythmia
Cholelethiasis or Cholecystitis
Chronic Bronchitis

Languages:

English

Description:

Dr. Liu graduated from the Tongji Med Univ, Wuhan City, Hubei, China in 1992. She works in Newton, NJ and specializes in Internal Medicine. Dr. Liu is affiliated with Overlook Medical Center.

Ping Liu

view source

Specialties:

Internal Medicine

Ping Liu, Newton NJ

view source

Specialties:

Internist

Address:

175 High St, Newton, NJ 07860
750 Brunswick Ave, Trenton, NJ 08638

Education:

Tongji Medical University - Doctor of Medicine
Abington Memorial Hospital - Residency - Internal Medicine

Board certifications:

American Board of Internal Medicine Certification in Internal Medicine

Resumes

Ping Liu Chapel Hill, NC

view source

Work:

UNC at Chapel Hill

Sep 2009 to 2000
Postdoctoral Fellow Stuart McLaughlin
Stony Brook, NY
Jul 2008 to Sep 2009
Postdoctoral Fellow

Education:

National University of Singapore
Singapore
2003 to 2008
Ph.D. in Biophysics Chinese Academy of Science
2000 to 2003
M.S. in Nonlinear Optics Xiamen University
1995 to 1999
B.S. in Chemistry

Skills:

Optical and Microscopic techniques Mastery of advanced fluorescence techniques, including fluorescence correlation spectroscopy (FCS) and cross-correlation spectroscopy (FCCS), fluorescence recovery after photobleaching (FRAP), Frster resonance energy transfer (FRET), total internal reflection fluorescence (TIRF), fluorescence lifetime imaging (FLIM), multi-photon imaging, and super-resolution microscopy (Blink, dSTORM). Expert in optical system construction and instrumentation, light pathway alignment, optic/microscope components design and system modification. Rich experience with home-built FCS/FCCS/TIRF systems. Professional with commercial confocal/spinning disk/multi-photon microscopes, and utilizing microscope techniques for life sciences applications. Familiar with software for both instrumentation and data processing, including AutoCAD, LabVIEW, Adobe Design Premium, MATLAB, Igor Pro, Mathematica, and Origin. Skilled in employing computational methods for in-depth study on nonlinear optics at quantum mechanics level, including Ab Initio and semi-empirical methods, density fluctuation theory, Monte Carlo and molecular dynamic simulations. Biomedical research Mastery of molecular biology techniques, biophysical/biochemical assays, and immunological methods, including: DNA cloning and plasmid amplification; protein expression, isolation and purification; 1D and 2D gel electrophoresis and mass spectrometry; western-blot; hybridoma culture, antibody extraction and purification; antibody and antigen labeling; primary cell culture, monocytes isolation and differentiation; cell microinjection; immunostaining; infectivity assay; fluorescence activated cell sorting (FACS); enzyme-based immunosorbent assay (ELISA); in vivo antigen tracking and live cell/animal model imaging. Specialized in cell membrane receptors involved in cancer research and pathology research. Intensive study on the epidermal growth factor (EGF) receptor family, the targets of various anti-cancer drugs; studies include receptor activation mechanism and signaling, intracellular Rho GTPases and effectors interactions. Intensive study on membrane C-type lectins expressed on human dendritic cells and macrophages; studies include lectin dynamics, lectin-mediated pathogens (yeasts and viruses) binding, virus entry, transportation and membrane fusions, and antibody neutralization mechanisms.

Ping Liu

view source

Work:

Ping Liu

2014 to 2000
Principal Statistician 3M Pharmaceuticals, Inc

May 2005 to Feb 2012
Statistician/lead statistician on several US and Europe

Aug 2000 to Apr 2005
Lead statistician in Actinic Keratosis project University of Minnesota

Sep 1998 to Jun 2000
Consultant

Education:

The University of Texas
2007 to 2012
Ph.D in Biostatistics University of Minnesota
1998 to 2000
M.S in Biostatistics Fudan University
1992 to 1997
B.S in Genetics & Genetic Engineering Fudan University